Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Transition Therapeutics
 More »

  • Cubist Acquires Two Antibiotics Developers in Deals Totaling...
    Cubist said yesterday it will acquire Trius Therapeutics for $818 million, as well as ... We expect a very smooth transition, and we look forward to its contributions to creating ...
    7-31-2013
  • Transition Scores Rights to Develop Lilly Osteoarthritis Pain...
    Transition Therapeutics is in-licensing TT-601, Eli Lilly's small molecule transcriptional regulator for the treatment of osteoarthritis (OA) pain. Per the agreement, Transition ...
    7-24-2013
  • Assay Development Driving Personalized Medicine
    The transition has already been rocky-the U.S. Centers for Medicare & Medicaid Services ... Yeh says. "As biomarker-driven therapeutics increase, there will not be enough tumor ...
    7-1-2013
  • Celgene, MorphoSys Ink Up to $818M Deal to Move Multiple Myeloma...
    ... deal also paves the way for MorphoSys' transition from a technology service provider to a ... MorphoSys' development as a biopharmaceutical company ... to a developer of therapeutics." ...
    6-27-2013
  • Transition Bags $7M from Lilly for Rights to Type 2 Diabetes...
    Transition Therapeutics this week said Eli Lilly and Company has exercised its option to assume all development and commercialization rights related to type 2 diabetes candidate ...
    6-18-2013
  • Biosimulation: Journey Through the Therapeutic Life Cycle
    to deliver highly efficacious low-risk therapeutics for subpopulations, these modeling ... remaining disease targets, the business transition from "me too" drug development, and the ...
    5-22-2013
  • The Tumor Microenvironment as a Drug Target, Part II
    ... This process results in the transition from dormant avascularized hyperplasia to ... can complicate the challenge of developing therapeutics to target cancer pathophysiology. ...
    5-7-2013
  • GEN | Biolinks
    ... Tosoh Bioscience Tragara Pharmaceuticals Transcept Pharmaceuticals TransGenRx Transition Therapeutics Tranzyme Pharma Trellis Bioscience Trevena Trigemina Trilink Biotechnologes ...
  • Single-Use Bioreactor Roundup
    ... to our equipment in a way that makes transition for the end-user as smooth as possible. ... the development of a new generation of therapeutics, the single-use bioreactor will be ...
    4-15-2013
  • En Bloc Analysis of Epigenetic Publications
    ... However, the endothelial-to-mesenchymal transition (EMT) segment is growing faster than ... for product vendors and diagnostics/therapeutics developers. | Gary Oosta, Ph.D. | Enal ...
    2-1-2013
  • Technologies Evolving for Cellular Therapies
    Unlike the market for small molecule therapeutics, stem cell and other biological ... company is working to enable a better transition from the preclinical research bench to ...
    1-15-2013
  • Companion Dx and Personalized Medicine
    Companion diagnostics, like the therapeutics they support, are pioneering personalized ... Roadblocks Regulation, reimbursement, and reluctance are slowing the transition to ...
    11-1-2012
  • Best Practices for Testing Biosimilarity During Clinical Trials
    companies have shifted their attention from small molecules to protein therapeutics. ... scientists may be making the transition to the challenge of large molecule production. ...
    10-22-2012
  • Tissue Engineering No Easy Cell
    partners, corporate (Pfizer and United Therapeutics) and academic (Harvard Medical School ... "What we're talking about here is a transition of biology into information technology, ...
    10-9-2012
  • All Eyes on Molecular Imaging
    ... Images convey the transition of classical methods to evaluate lung disease, histology, to ... tool to quantify the degree of lung disease and improvement with novel therapeutics. ...
    8-1-2012
  • More »

    Journal Articles

  • Race, Socioeconomic Status, and Treatment Center Are Associated...
    Maria H. Lin, Crystal G. Connor, Katrina J. Ruedy, Roy W. Beck, Craig Kollman, Bruce Buckingham, Maria J. Redondo, Desmond Schatz, Heidi Haro, Joyce M. Lee, William V. Tamborlane, Jamie R. Wood, for the Pediatric Diabetes Co
    Diabetes Technology & Therapeutics
    Diabetes Technology & Therapeutics Background: An increasing number of children and ... Logistic regression was used to determine factors associated with transition from ...
  • Human Hp1-1 and Hp2-2 Phenotype-Specific Haptoglobin Therapeutics...
    Miriam Lipiski, Jeremy W. Deuel, Jin Hyen Baek, Wolfgang R. Engelsberger, Paul W. Buehler, Dominik J. Schaer
    Antioxidants & Redox Signaling
    Both phenotypes stabilize the ferryl (Fe4+) Hb transition state, provide heme retention ... the concept that phenotype specific Hp therapeutics offer differential efficacy in ...
  • Hyperemia-Associated Costs of Medication Changes in Glaucoma...
    Gail F. Schwartz, Jason Tan, Sameer Kotak
    Journal of Ocular Pharmacology and Therapeutics
    Journal of Ocular Pharmacology and Therapeutics Aims: To develop a model to estimate and ... Transition rates reflected events related to reports of hyperemia where a physician-driven ...
  • Intraocular Pressure Control Among Patients Transitioned From...
    Steven H. McKinley, Ruhi Singh, Peter T. Chang, Ronald L. Gross, Silvia Orengo-Nania
    Journal of Ocular Pharmacology and Therapeutics
    Journal of Ocular Pharmacology and Therapeutics Purpose: To evaluate intraocular pressure (IOP) control and the ocular adverse effects resulting from a large-scale transition from ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll